ZA201407369B - Self-stabilizing linker conjugates - Google Patents

Self-stabilizing linker conjugates

Info

Publication number
ZA201407369B
ZA201407369B ZA2014/07369A ZA201407369A ZA201407369B ZA 201407369 B ZA201407369 B ZA 201407369B ZA 2014/07369 A ZA2014/07369 A ZA 2014/07369A ZA 201407369 A ZA201407369 A ZA 201407369A ZA 201407369 B ZA201407369 B ZA 201407369B
Authority
ZA
South Africa
Prior art keywords
self
linker conjugates
stabilizing linker
stabilizing
conjugates
Prior art date
Application number
ZA2014/07369A
Other languages
English (en)
Inventor
Doronina Svetlana
Lyon Robert
Bovee Timothy
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/799,244 external-priority patent/US9504756B2/en
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of ZA201407369B publication Critical patent/ZA201407369B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Insulating Materials (AREA)
  • External Artificial Organs (AREA)
ZA2014/07369A 2012-05-15 2014-10-10 Self-stabilizing linker conjugates ZA201407369B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261647373P 2012-05-15 2012-05-15
US201361770983P 2013-02-28 2013-02-28
US201361773067P 2013-03-05 2013-03-05
US13/799,244 US9504756B2 (en) 2012-05-15 2013-03-13 Self-stabilizing linker conjugates
PCT/US2013/040951 WO2013173337A2 (en) 2012-05-15 2013-05-14 Self-stabilizing linker conjugates

Publications (1)

Publication Number Publication Date
ZA201407369B true ZA201407369B (en) 2020-02-26

Family

ID=49584442

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/07369A ZA201407369B (en) 2012-05-15 2014-10-10 Self-stabilizing linker conjugates

Country Status (15)

Country Link
EP (1) EP2850094B1 (cg-RX-API-DMAC7.html)
JP (5) JP6423340B2 (cg-RX-API-DMAC7.html)
KR (5) KR20230113821A (cg-RX-API-DMAC7.html)
CN (2) CN104822656B (cg-RX-API-DMAC7.html)
AU (5) AU2013263002C1 (cg-RX-API-DMAC7.html)
BR (1) BR112014028222A2 (cg-RX-API-DMAC7.html)
CA (2) CA3131619A1 (cg-RX-API-DMAC7.html)
EA (1) EA037203B1 (cg-RX-API-DMAC7.html)
ES (1) ES2983109T3 (cg-RX-API-DMAC7.html)
HK (1) HK1207388A1 (cg-RX-API-DMAC7.html)
MX (2) MX384366B (cg-RX-API-DMAC7.html)
NZ (3) NZ741211A (cg-RX-API-DMAC7.html)
SG (2) SG11201406252WA (cg-RX-API-DMAC7.html)
WO (1) WO2013173337A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201407369B (cg-RX-API-DMAC7.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
TWI603741B (zh) 2011-06-10 2017-11-01 梅爾莎納醫療公司 蛋白質-聚合物-藥物共軛體
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
MX384366B (es) * 2012-05-15 2025-03-14 Seagen Inc Conjugados enlazadores auto-estabilizantes.
KR102572149B1 (ko) 2013-10-11 2023-08-30 아사나 바이오사이언시스 엘엘씨 단백질-폴리머-약물 접합체
DK3054991T3 (da) 2013-10-11 2019-05-06 Mersana Therapeutics Inc Protein-polymer-lægemiddelkonjugater
KR102356814B1 (ko) * 2013-10-15 2022-01-28 씨젠 인크. 개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
CA2932647C (en) 2013-12-19 2022-06-14 Seattle Genetics, Inc. Methylene carbamate linkers for use with targeted-drug conjugates
WO2016008112A1 (en) * 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
ES2987765T3 (es) * 2014-09-11 2024-11-18 Seagen Inc Suministro dirigido de sustancias farmacéuticas que contienen amina terciaria
CA2962783A1 (en) * 2014-10-01 2016-04-07 Medimmune, Llc Method of conjugating a polypeptide
EP3210623B1 (en) 2014-10-24 2022-10-05 NOF Corporation Antibody-drug complex having cyclic benzylidene acetal linker
CA2969689A1 (en) * 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
JP2018502839A (ja) * 2014-12-09 2018-02-01 アッヴィ・インコーポレイテッド Ｂｃｌ−ｘＬ阻害性化合物およびこれを含む抗体薬物コンジュゲート
CA2970155A1 (en) * 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
EP3270965B1 (en) 2015-03-18 2020-05-06 Seattle Genetics, Inc. Cd48 antibodies and conjugates thereof
CN106267225B (zh) 2015-05-29 2020-03-06 上海新理念生物医药科技有限公司 三马来酰亚胺型连接子及其应用
CN111533778B (zh) * 2015-07-28 2023-04-25 上海皓元生物医药科技有限公司 一种抗体偶联药物连接子的工业化生产方法
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017165851A1 (en) 2016-03-25 2017-09-28 Seattle Genetics, Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
EP3442979A4 (en) 2016-04-04 2019-12-18 Rutgers, the State University of New Jersey topoisomerase poisons
WO2017196598A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
CN116173232A (zh) 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
PH12018502602B1 (en) 2016-06-08 2023-08-16 Abbvie Inc Anti-egfr antibody drug conjugates
JP2019521114A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
MY199278A (en) 2016-06-08 2023-10-24 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
CN109562190A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
KR20190038579A (ko) * 2016-08-09 2019-04-08 시애틀 지네틱스, 인크. 개선된 물리화학적 특성을 갖는 자기 안정화 링커를 구비한 약물 접합체
CN118359705A (zh) 2016-10-19 2024-07-19 英温拉公司 抗体构建体
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
KR102312222B1 (ko) 2016-12-22 2021-10-12 우니베르시따 델리 스투디 만냐 그레챠 카탄차로 Ｃｄ43의 독특한 시알로글리코실화된 암-연관 에피토프를 표적으로 하는 모노클로날 항체
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
CN107652219B (zh) 2017-08-14 2021-06-08 上海新理念生物医药科技有限公司 四马来酰亚胺型连接子及其应用
CN111601803A (zh) 2017-09-08 2020-08-28 西雅图基因公司 微管溶素及其中间体的制备方法
US11707531B2 (en) * 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
SG11202011984UA (en) 2018-06-05 2020-12-30 King S College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US20220040320A1 (en) * 2018-12-21 2022-02-10 Seagen Inc. Adcs with thiol multiplex linkers
WO2020259258A1 (zh) * 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 一种抗体偶联药物、其中间体、制备方法及应用
CA3152316A1 (en) 2019-10-04 2021-04-08 Scott C. Jeffrey Camptothecin peptide conjugates
US20230173093A1 (en) * 2020-04-10 2023-06-08 Seagen Inc. Charge variant linkers
WO2021226454A1 (en) * 2020-05-08 2021-11-11 Mpeg La, L.L.C. Linker compounds
EP4223741A1 (en) * 2020-09-29 2023-08-09 Mabwell (Shanghai) Bioscience Co., Ltd. Preparation method for bis-substituted bridging antibody-drug conjugate
CA3200812A1 (en) 2020-12-04 2022-06-09 Qingsong GUO Antibody-drug conjugate, and intermediate thereof, preparation method thereof, and application thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2022198231A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3254933A1 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
AU2023298568A1 (en) 2022-06-30 2025-01-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
IL320524A (en) * 2022-10-28 2025-06-01 Lilly Co Eli Self-hydrolyzing maleimides for bioconjugation
TW202435917A (zh) 2022-11-17 2024-09-16 美商西雅圖遺傳學公司 Ceacam5抗體-藥物接合物及其使用方法
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
IL322569A (en) * 2023-02-09 2025-10-01 Beone Medicines I Gmbh Self-stabilizing bonding material bracelets
WO2024220889A1 (en) 2023-04-20 2024-10-24 Seagen Inc. Sting agonist compounds and conjugates thereof
WO2024258743A1 (en) 2023-06-13 2024-12-19 Adcentrx Therapeutics, Inc. Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
TW202500198A (zh) * 2023-06-29 2025-01-01 瑞士商百濟神州瑞士有限責任公司 生物活性偶聯物、其製備方法及用途
WO2025054181A1 (en) 2023-09-05 2025-03-13 Seagen Inc. Targeted degrader molecules and ligand drug conjugates thereof
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2036891B (en) 1978-12-05 1983-05-05 Windsor Smith C Change speed gear
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5091542A (en) * 1990-03-09 1992-02-25 Hybritech Incorporated Tris-maleimido compounds as intermediates in trifunctional antibody synthesis
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
WO1994001485A1 (en) * 1992-07-01 1994-01-20 Akzo Nobel N.V. Process for the modification of polyphenylene ether resin compositions
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6130237A (en) 1996-09-12 2000-10-10 Cancer Research Campaign Technology Limited Condensed N-aclyindoles as antitumor agents
US5973166A (en) 1998-03-02 1999-10-26 The Dexter Corporation Method for the preparation of maleimides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US8877901B2 (en) * 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP2353611B1 (en) 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
RU2402548C2 (ru) 2004-05-19 2010-10-27 Медарекс, Инк. Химические линкеры и их конъюгаты
AU2005249490B2 (en) 2004-06-01 2010-07-29 Genentech, Inc. Antibody drug conjugates and methods
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US8343928B2 (en) 2005-07-07 2013-01-01 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain replacements at the C-terminus
NZ566982A (en) 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
ATE527262T1 (de) 2006-01-25 2011-10-15 Sanofi Sa Neue tomaymycin derivate enhaltende zytotoxische mittel
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
ES2523033T3 (es) 2008-03-18 2014-11-20 Seattle Genetics, Inc. Conjugados enlazadores del fármaco auriestatina
RU2503687C2 (ru) 2008-04-30 2014-01-10 Иммьюноджен, Инк. Сшивающие реагенты и их применение
BRPI0923283A2 (pt) * 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
EP3360879A1 (en) 2009-02-05 2018-08-15 ImmunoGen, Inc. Benzodiazepine derivatives as cytotoxic agents
PT3903829T (pt) * 2009-02-13 2023-06-02 Immunomedics Inc Imunoconjugados com uma ligação intracelular clivável
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
RS52983B (sr) 2010-04-15 2014-02-28 Spirogen Sárl Pirolobenzodiazepini i njihovi konjugati
TWI545134B (zh) * 2010-10-22 2016-08-11 西雅圖遺傳學公司 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效
RS58620B1 (sr) 2011-02-15 2019-05-31 Immunogen Inc Metodi pripremanja konjugata
MX384366B (es) * 2012-05-15 2025-03-14 Seagen Inc Conjugados enlazadores auto-estabilizantes.
WO2014151030A1 (en) * 2013-03-15 2014-09-25 Novartis Ag Cell proliferation inhibitors and conjugates thereof

Also Published As

Publication number Publication date
JP2018162251A (ja) 2018-10-18
NZ630870A (en) 2016-10-28
NZ724892A (en) 2018-04-27
AU2023203005A1 (en) 2023-06-01
AU2018201190B2 (en) 2020-01-30
AU2021201636B2 (en) 2023-02-16
WO2013173337A3 (en) 2015-06-11
JP2024032941A (ja) 2024-03-12
KR20220166877A (ko) 2022-12-19
SG11201406252WA (en) 2014-10-30
CN108465112B (zh) 2022-04-29
JP6423340B2 (ja) 2018-11-14
AU2021201636A1 (en) 2021-04-08
JP6709247B2 (ja) 2020-06-10
KR102433686B1 (ko) 2022-08-19
AU2013263002B2 (en) 2017-11-30
JP2015521187A (ja) 2015-07-27
BR112014028222A2 (pt) 2017-06-27
HK1207388A1 (en) 2016-01-29
AU2013263002A1 (en) 2014-09-25
SG10201608904YA (en) 2016-12-29
EP2850094A4 (en) 2016-07-06
KR102475777B1 (ko) 2022-12-09
MX2019012201A (es) 2019-11-28
JP2022044690A (ja) 2022-03-17
AU2013263002C1 (en) 2018-05-31
KR20200097000A (ko) 2020-08-14
ES2983109T3 (es) 2024-10-21
EP2850094B1 (en) 2024-04-17
AU2020202805B2 (en) 2020-12-17
MX368678B (es) 2019-10-11
CA2869777A1 (en) 2013-11-21
CN104822656A (zh) 2015-08-05
WO2013173337A2 (en) 2013-11-21
CN104822656B (zh) 2018-05-01
MX384366B (es) 2025-03-14
KR102144069B1 (ko) 2020-08-13
AU2020202805A1 (en) 2020-05-21
NZ741211A (en) 2019-09-27
KR20230113821A (ko) 2023-08-01
JP2020122023A (ja) 2020-08-13
KR20150009991A (ko) 2015-01-27
JP7431261B2 (ja) 2024-02-14
MX2014013807A (es) 2015-02-04
CA3131619A1 (en) 2013-11-21
EA037203B1 (ru) 2021-02-18
CA2869777C (en) 2021-11-16
EA201401254A1 (ru) 2015-09-30
KR102557309B1 (ko) 2023-07-20
JP7014856B2 (ja) 2022-02-01
EP2850094A2 (en) 2015-03-25
CN108465112A (zh) 2018-08-31
KR20210094150A (ko) 2021-07-28
AU2018201190A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
HUS2300020I1 (hu) Pirrolobenzodiazepin-antitest konjugátumok
ZA201407369B (en) Self-stabilizing linker conjugates
IL268420A (en) Oligonucleotide conjugates
ZA201900820B (en) Antibody-drug conjugate
IL263973B (en) Protein-polymer-drug conjugates
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
ZA201501996B (en) Drug-protein conjugates
IL237672A0 (en) Drug-protein conjugates
IL228404A0 (en) Antibody-drug captures
PL2717917T3 (pl) Koniugaty p97 - przeciwciało
ZA201409119B (en) Polymer-nsaid conjugate
IL233701B (en) Conjugates of a binding molecule